All In Biotech

Drug Trial Radar · NCT07873463

Flutemetamol F 18 Injection Formulation Comparison

A Multicenter, Phase 2, Open-Label, Randomized, Crossover Comparison of Two Formulations of Flutemetamol F 18 Injection

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Feb 25, 2027

Study completion Feb 25, 2027

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 110 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other conditions affecting memory or thinking. A new formulation of this drug, called GE-287, has been developed. This new formulation may offer advantages for patient tolerability and can be produced more reliably and efficiently. The aim of the study is to determine whether the new formulation works as well as the current one in identifying amyloid in the brain, how it distributes in the body, and whether it is safe for use. The study will measure how much of the study drug goes to different organs (including the brain, heart, liver, and kidneys) and monitor for any side effects.

Conditions

  • Cognitive Dysfunction

Interventions

  • GE-287Drug

    Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously

  • VizamylDrug

    Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously

  • VizamylDrug

    Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously

  • GE-287Drug

    Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain regionTime frame: 90-100 minutes after product administration
  2. Comparison of SUVr in posterior cingulate and precuneus brain regionTime frame: 90-100 minutes after product administration
  3. Comparison of SUVr in lateral temporal brain regionTime frame: 90-100 minutes after product administration
  4. Comparison of SUVr in inferolateral parietal brain regionTime frame: 90-100 minutes after product administration
  5. Comparison of Standard Uptake Value (SUV) in heartTime frame: 0-60 minutes after product administration
  6. Comparison of SUV in liverTime frame: 0-60 minutes after product administration
  7. Comparison of SUV in kidneysTime frame: 0-60 minutes after product administration

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Visionary Investigator Network

    Aventura, Florida · Recruiting

  • Meritt Island Research, LLC dba. Flourish Research

    Merritt Island, Florida · Not yet recruiting

  • Visionary Investigator Network

    Miami, Florida · Recruiting

  • Visionary Investigator Network

    Miami, Florida · Recruiting

  • Clinical Site Partners, LLC dba Flourish Research

    Winter Park, Florida · Recruiting

  • Center for Advanced Research & Education LLC dba Flourish Research Gainesville

    Gainesville, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.